



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	337774 Lifelong Vitality Pack
ARTG entry for	Medicine Listed
Sponsor	doTERRA Australia Pty Ltd
Postal Address	102 / 271 Wellington Road, Mulgrave, VIC, 3170 Australia
ARTG Start Date	12/06/2020
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Lifelong Vitality Pack

Product Type	Medicine Kit	Effective Date	8/07/2020
---------------------	--------------	-----------------------	-----------

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Indications

- BDAOB-S-RD Antioxidant/reduce free radicals formed in the body.
- IMHEF-G-MS Maintain/support healthy immune system function.
- IMHE-G-MS Maintain/support immune system health.
- BDGHW-G-MS Maintain/support general health and wellbeing.
- BDENFO-S-CN Helps convert (Fats and Carbohydrates) into energy.
- BDENP-S-MS Maintain/support energy production.
- BDHRH-G-MS Maintain/support hair health.
- BDNAH-G-MS Maintain/support nail health/strength/thickness.
- NUVMMT-S-AA Aid/assist/helps metabolism of (Carbohydrates, Fats & Proteins).
- SKSTH-G-MS Maintain/support skin health.
- NUVMDF-S-PV Helps prevent dietary Biotin, Magnesium, Calcium, Vitamin C, Folate, Pantothenic acid, Chromium, Vitamin D, Copper, Vitamin B12, Vitamin E, Niacin, Vitamin K, Pyridoxine, Vitamin A, Riboflavin, Selenium, Thiamine, Zinc, Omega-3 fatty acid deficiency.
- BOHE-S-MS Maintain/support bone health.
- CVH-G-MS Maintain/support cardiovascular system health.
- CVHEFU-G-MS Maintain/support healthy cardiovascular system function.
- CVHEHE-G-MS Maintain/support heart health.
- BDEN-G-MS Maintain/support energy levels.
- MUHF-G-MS Maintain/support muscle function.
- NVHSY-G-MS Maintain/support nervous system health.
- NVHSYFU-G-MS Maintain/support nervous system function.
- NVHCN-S-MS Maintain/support nerve conduction.
- MUHNE-G-MS Maintain/support healthy neuromuscular system/function.
- BOHEST-G-MS Maintain/support bone strength.
- BOHMN-S-MS Help maintain/support bone mineralisation.
- BOHEM-S-MS Maintain/support bone mass/density/integrity.
- BOJOARC-S-PV A diet deficient in calcium can lead to osteoporosis in later life. Calcium may help prevent osteoporosis when dietary intake is inadequate.



Australian Government
Department of Health
 Therapeutic Goods Administration

GIDIF-G-MS Maintain/support healthy digestive system function.
 GIDIH-G-MS Maintain/support healthy digestion.
 MUHCN-G-MS Maintain/support healthy muscle contraction function.
 NVHNMF-S-MS Maintain/support neuromuscular function.
 BDCOF-S-MS Maintain/support collagen formation.
 BDTSC-G-MS Maintain/support connective tissue health.
 BDTSCT-S-AA Aid/assist/helps connective tissue production/formation.
 CVVCAF-S-MS Maintain/support blood capillary health.
 CVVEH-S-MS Maintain/support blood vessel health.
 NVHNTSY-S-AA Aid/assist/helps synthesis of neurotransmitters.
 NUVMAB-S-MS Maintain/support absorption of dietary Iron.
 SKWOHL-G-MS Maintain/support wound healing.
 CVBCRCP-S-AA Aid/assist healthy red blood cell production.
 NUVMMT-S-AA Aid/assist/helps metabolism of (proteins).
 NUNUPR-S-AA Aid/assist/helps protein synthesis in the body.
 NVAXADEN-G-AA Aids/assists the body to cope with environmental stress.
 NVAXADSTRE-G-MS Support healthy stress response in the body.
 NUNUGM-S-AA Aid/assist/helps glucose/sugar/carbohydrate metabolism.
 NUVMMT-S-AA Aid/assist/helps metabolism of (Carbohydrate, Lipid and Protein).
 BOJOAVD-S-PV Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life.
 NUVMAB-S-MS Maintain/support absorption of dietary (Calcium and Phosphorus).
 NUVML-S-MS Maintain/support (Calcium) levels in the body.
 NUVML-S-MS Maintain/support (Vitamin D) levels in the body when sun exposure is inadequate.
 NUVML-S-MS Maintain/support (Vitamin D) levels in the body in elderly individuals when sun exposure is inadequate.
 BDCOH-S-MS Maintain/support collagen health.
 CVBRCH-S-MS Helps maintain/support haemoglobin formation/synthesis.
 NUVMMT-S-AA Aid/assist/helps metabolism of Iron.
 CVBLHE-G-MS Maintain/support blood health.
 CVBLOX-S-MS Helps maintain/support transport of oxygen in the body.
 CVBLOXT-S-AA Aid/assist/helps oxygen transport to body tissues.
 BDENFO-S-CN Helps convert (food) into energy.
 SKSTRIN-G-MS Maintain/support skin integrity/structure.
 BDTSH-G-MS Maintain/support healthy body tissues.
 CVBCRH-S-MS Maintain/support red blood cell health.
 BDHRG-G-MS Maintain/support hair growth.
 BDNAH-G-MS Maintain/support nail health/strength/thickness.
 BDNAG-G-AA Aid/assist nail growth.
 ENDTHPR-S-AA Aid/assist thyroid hormone production.
 ENDTHHO-S-MS Maintain/support healthy thyroid hormones.
 ENDTHFU-G-MS Maintain/support healthy thyroid gland function.
 NVBRCGFU-G-MS Maintain/support cognitive function/mental function.
 SKSTRIN-G-MS Maintain/support skin integrity/structure.
 SKSTRRG-G-MS Maintain/support skin regeneration.
 BDEYHE-G-MS Maintain/support eye health.
 BDEYHRET-S-MS Helps maintain/support eye retina health.
 BDEYVI-G-MS Maintain/support healthy eyesight/vision.
 NVBRFN-G-MS Maintain/support brain function.

Warnings

Do not take while on warfarin therapy without medical advice.
 This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.
 (If medicine contains one benzoate) Contains [insert name of benzoate] Or (If medicine contains two or more benzoates) Contains benzoates [or words to that effect].

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

- 1 . xEO Mega (ARTG: 327961)
- 2 . Alpha CRS+ (ARTG: 285193)
- 3 . Microplex VMz (ARTG: 336370)



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	336370	Microplex VMz
ARTG entry for	Medicine Listed	
Sponsor	doTERRA Australia Pty Ltd	
Postal Address	102 / 271 Wellington Road, Mulgrave, VIC, 3170 Australia	
ARTG Start Date	14/05/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Microplex VMz

Product Type	Single Medicine Product	Effective Date	14/05/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Maintain/support collagen formation
- Maintain/support collagen health
- Maintain/support energy levels
- Helps convert (state food) into energy
- Maintain/support energy production
- Maintain/support general health and wellbeing
- Maintain/support hair growth
- Maintain/support hair health
- Aid/assist nail growth
- Maintain/support nail health/strength/thickness
- Maintain/support connective tissue health
- Aid/assist/helps connective tissue production/formation
- Maintain/support healthy body tissues
- Maintain/support bone health
- Maintain/support bone mass/density/integrity
- Maintain/support bone strength
- Help maintain/support bone mineralisation
- A diet deficient in calcium can lead to osteoporosis in later life. Calcium may help prevent osteoporosis when dietary intake is inadequate
- Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life
- Aid/assist healthy red blood cell production
- Maintain/support red blood cell health
- Maintain/support blood health

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Helps maintain/support transport of oxygen in the body
Aid/assist/helps oxygen transport to body tissues
Helps maintain/support haemoglobin formation/synthesis
Maintain/support cardiovascular system health
Maintain/support healthy cardiovascular system function
Maintain/support heart health
Maintain/support blood capillary health
Maintain/support blood vessel health
Maintain/support healthy thyroid gland function
Maintain/support healthy thyroid hormones
Aid/assist thyroid hormone production
Maintain/support healthy digestive system function
Maintain/support immune system health
Maintain/support healthy immune system function
Maintain/support healthy muscle contraction function
Maintain/support muscle function
Maintain/support healthy neuromuscular system/function
Aid/assist/helps glucose/sugar/carbohydrate metabolism
Aid/assist/helps protein synthesis in the body
Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
Maintain/support (state vitamin/mineral/nutrient) levels in the body when sun exposure is inadequate
Maintain/support (state vitamin/mineral/nutrient) levels in the body when sun exposure is inadequate in elderly individuals
Maintain/support (state vitamin/mineral/nutrient) levels in the body
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
Aids/assists the body to cope with environmental stress
Support healthy stress response in the body
Maintain/support cognitive function/mental function
Maintain/support nerve conduction
Maintain/support neuromuscular function
Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system health
Maintain/support nervous system function
Maintain/support skin health
Maintain/support skin integrity/structure
Maintain/support skin regeneration
Maintain/support wound healing

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.
Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.
Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.
Product presentation must not imply or refer to serious cardiovascular conditions.
Product presentation must not imply or refer to heart disease.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Indication can only be used for medicines that contain calcium as an active ingredient and the recommended daily dose of the medicine must provide at least 290 milligrams of elemental calcium.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Product presentation must not imply or refer to any thyroid related diseases.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Label statement: If symptoms persist, talk to your health professional.



Australian Government
Department of Health
 Therapeutic Goods Administration

Product presentation must not imply or refer to serious immunological diseases.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

(If medicine contains one benzoate) Contains [insert name of benzoate] Or (If medicine contains two or more benzoates) Contains benzoates [or words to that effect].

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Amylase	111 DU
betacarotene	.923 mg
Biotin	75 microgram
Brassica oleracea var. capitata leaf Powder	1.38 mg
Brassica oleracea var. gemmifera leaf bud Powder	1.38 mg
Brassica oleracea var. italica sprout Extract dry concentrate	1.38 mg
Equivalent: Brassica oleracea var. italica (Dry)	414 mg
Brassica oleracea var. viridis leaf Powder	5.63 mg
calcified lithothamnion species	93.75 mg
Equivalent: magnesium	2.06 mg
Equivalent: calcium	30 mg
calcium ascorbate dihydrate	45.39 mg
Equivalent: calcium	4.27 mg
Equivalent: ascorbic acid	37.5 mg
calcium carbonate	226.26 mg
Equivalent: calcium	90.5 mg
calcium folinate	138.89 microgram
Equivalent: folic acid	100 microgram
calcium pantothenate	2.73 mg
Equivalent: pantothenic acid	2.5 mg
Carum carvi seed Extract dry concentrate	2.5 mg
Equivalent: Carum carvi (Dry)	10 mg
cellulase	55 CU
chromium nicotinate	104.17 microgram
Equivalent: chromium	12.5 microgram
colecalfiferol	.0012 mg

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

copper gluconate	892.86 microgram
Equivalent: copper	125 microgram
cyanocobalamin	2.5 microgram
d-alpha-tocopheryl acid succinate	10.33 mg
Fucus vesiculosus whole plant Powder	12.5 mg
iron (II) glycinate	5.4785 mg
Equivalent: iron	1.5 mg
lipase	37 LipU
magnesium amino acid chelate	185.63 mg
Equivalent: magnesium	37.13 mg
magnesium ascorbate monohydrate	13.93 mg
Equivalent: magnesium	862.21 microgram
Equivalent: ascorbic acid	12.5 mg
manganese amino acid chelate	1.25 mg
Equivalent: manganese	125 microgram
Mentha X piperita leaf Extract dry concentrate	2.5 mg
Equivalent: Mentha X piperita (Dry)	10 mg
nicotinamide	5 mg
palm tocotrienols complex	96.5 microgram
Petroselinum crispum herb Powder	3.38 mg
phytomenadione	5 microgram
protease	3.066 Thousand HUT
pyridoxine hydrochloride	911.65 microgram
Equivalent: pyridoxine	750 microgram
retinol acetate	86.25 microgram
riboflavin	750 microgram
selenomethionine	43.47 microgram
Equivalent: selenium	17.5 microgram
Spinacia oleracea leaf Powder	1.38 mg
Taraxacum officinale leaf Extract dry concentrate	3.38 mg
Equivalent: Taraxacum officinale (Dry)	16.9 mg
thiamine hydrochloride	840.94 microgram
Equivalent: thiamine	750 microgram
tilactase	69 ALU
zinc amino acid chelate	18.75 mg
Equivalent: zinc	3.75 mg
Zingiber officinale root Extract dry concentrate	2.5 mg
Equivalent: Zingiber officinale (Dry)	50 mg

Other Ingredients (Excipients)

Acacia
butylated hydroxytoluene
calcium hydrogen phosphate dihydrate
citric acid
colloidal anhydrous silica
croscarmellose sodium
crospovidone
dextrin
dl-alpha-tocopherol
ethylcellulose
Gelatin
glucose monohydrate

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

hypromellose
liquid paraffin
magnesium stearate
maize starch
maltodextrin
medium chain triglycerides
microcrystalline cellulose
Pea Starch
pregelatinised maize starch
purified water
silicon dioxide
sodium alginate
sodium benzoate
sucrose
tartaric acid

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	327961	xEO Mega
ARTG entry for	Medicine Listed	
Sponsor	doTERRA Australia Pty Ltd	
Postal Address	102 / 271 Wellington Road, Mulgrave, VIC, 3170 Australia	
ARTG Start Date	20/12/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . xEO Mega

Product Type	Single Medicine Product	Effective Date	24/02/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support eye health
- Helps maintain/support eye retina health
- Maintain/support healthy eyesight/vision
- Maintain/support general health and wellbeing
- Maintain/support bone health
- Maintain/support bone strength
- Help maintain/support bone mineralisation
- Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life
- Maintain/support cardiovascular system health
- Maintain/support healthy cardiovascular system function
- Maintain/support heart health
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Maintain/support muscle function
- Maintain/support healthy neuromuscular system/function
- Maintain/support absorption of dietary (state vitamin/mineral/nutrient)
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Maintain/support (state vitamin/mineral/nutrient) levels in the body when sun exposure is inadequate
- Maintain/support (state vitamin/mineral/nutrient) levels in the body when sun exposure is inadequate in elderly individuals
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
- Maintain/support brain function

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Maintain/support wound healing

Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Label statement: If symptoms persist, talk to your health professional.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Capsule, soft
Route of Administration	Oral

Visual Identification

Active Ingredients

astaxanthin esters extracted from Haematococcus pluvialis	2 mg
Equivalent: Astaxanthin (of Haematococcus pluvialis)	250 microgram
betacarotene	1.0009 mg
Borago officinalis seed Oil fixed	50 mg
Caraway Oil	2.286 mg
Chamomile Oil German	285 microgram
colecalfiferol	5 microgram
concentrated fish Omega-3 triglycerides	179.028 mg
concentrated fish Omega-3 triglycerides	81 mg
Equivalent: eicosapentaenoic acid	8.1 mg
Equivalent: docosahexaenoic acid	40.5 mg
Cumin Oil	3.429 mg
d-alpha-tocopherol	10.1 mg
Ginger Oil	2.856 mg
lutein	.75 mg
lycopene	.25 mg
Olibanum Oil	4.572 mg
Orange Oil	3.429 mg

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Peppermint Oil	3.429 mg
Punica granatum seed Oil fixed	12.5 mg
Syzygium aromaticum whole plant Oil essential	5.715 mg
Thyme Oil	3.999 mg
zeaxanthin	.2504 mg

Other Ingredients (Excipients)

d-alpha-tocopherol
dl-alpha-tocopherol
glycerol
lecithin
Maize Oil
mixed (low-alpha type) tocopherols concentrate
modified food starch
Olive Oil
purified water
Rosmarinus officinalis
Safflower Oil
Sunflower Oil
vegetable oil

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	285193	Alpha CRS+
ARTG entry for	Medicine Listed	
Sponsor	doTERRA Australia Pty Ltd	
Postal Address	102 / 271 Wellington Road, Mulgrave, VIC, 3170 Australia	
ARTG Start Date	3/02/2017	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27) as in force or existing from time to time. This condition does not apply to powdered or dried leaf.

Products

1 . Alpha CRS+

Product Type	Single Medicine Product	Effective Date	8/07/2020
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Maintain/support energy production
- Maintain/support general health and wellbeing

Indication Requirements

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not take while on warfarin therapy without medical advice.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

acetyl levocarnitine hydrochloride	29.48 mg
alpha lipoic acid	25 mg
Boswellia serrata gum oleoresin Extract dry concentrate standardised	76.92 mg
Equivalent: Boswellia serrata (Dry)	461.54 mg
bromelains	4.17 mg
Camellia sinensis leaf Extract dry concentrate standardised	9.04 mg
Equivalent: Camellia sinensis (Dry)	271.2 mg
Carum carvi seed Extract dry concentrate	2.5 mg
Equivalent: Carum carvi (Dry)	10 mg
curcumin	7.89 mg
Ginkgo biloba leaf Extract dry concentrate standardised	200 microgram
Equivalent: Ginkgo biloba (Dry)	10 mg
Mentha X piperita leaf Extract dry concentrate	2.5 mg
Equivalent: Mentha X piperita (Dry)	10 mg
Pinus pinaster	2.61 mg
Punica granatum seed Extract dry concentrate	15.63 mg
Equivalent: Punica granatum (Dry)	781.25 mg
quercetin dihydrate	12.5 mg
Reynoutria japonica root Extract dry concentrate standardised	25 mg
Equivalent: Reynoutria japonica (Dry)	2.5 g
Scutellaria baicalensis root Extract dry concentrate	44.12 mg
Equivalent: Scutellaria baicalensis (Dry)	573.53 mg
Sesamum indicum seed Extract dry concentrate	5 mg
Equivalent: Sesamum indicum (Dry)	20 mg
Silybum marianum fruit Extract dry concentrate standardised	31.25 mg
Equivalent: Silybum marianum (Dry)	2.1875 g
ubidecarenone	12.5 mg
Vitis vinifera seed Extract dry concentrate standardised	5.2632 mg
Equivalent: Vitis vinifera (Dry)	631.58 mg
Zingiber officinale root Extract dry concentrate	2.5 mg
Equivalent: Zingiber officinale (Dry)	50 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
carrageenan
colloidal anhydrous silica
croscarmellose sodium
glucose monohydrate
hypromellose
magnesium stearate
maltodextrin
microcrystalline cellulose
potassium acetate
purified water
soy polysaccharide

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary